ChromaDex (CDXC) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall St set for lower open as Alphabet results reignite AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
August 3, 2021 4:02 PM EDTTru Niagen® net sales of $15.4 million for the three months ended June 30, 2021, up 31% from the prior year quarter, with total company net sales of $17.7 million and gross margin of 61.1% for the quarter.
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the second quarter of 2021.
Second Quarter 2021 and Recent Highlights
Total net sales were $17.7 million, up 16% from the prior year quarter. Tru Niagen® net sales were $15.4 million, a 31% increase from the prior year quarter. Gross... More


